Michinori Akaiwa
Senior Director & Head of ADC Biologics Engineering, Oncology Research Astellas
I started my career in Astellas since 2008 and have 8 years small molecule project experiences including Kras inhibitor led to Astellas Kras degrader pipeline. My ADC work started at Agensys acquired by Astellas, since then more than 9 years ADC experiences such as new Linker development, Payload optimization and dual payload ADC with external partners.
Seminars
Thursday 11th June 2026
Exploring Next-Generation ADCs: Future Insight for Dual Payload ADCs
8:00 am
- Showcasing traditional cytotoxic ADC development and combination of IO drug, headlined by the approval and success of Padcev
- Exploring next-generation ADCs delivering an immune agonist payload and their expansion toward next-generation immunostimulatory dual payload ADC
- Discussing a strategy for a next-generation ADC, challenges and solutions
